Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Chengdu Kanghong Pharmaceutical Group is a Shenzhen-listed (SZSE: 002773) company. Its anti-VEGF eye drug conbercept (Langmu) is approved in China.
| Headquarters | Chengdu, China |
|---|---|
| Listing | SZSE:002773 |
| Lead asset / stage | conbercept (Langmu) Approved — China |
| Latest event | Kanghong announced inclusion in the 2026 list of 500 private enterprises by R&D investment. |